

Anthony Rodgers

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7794711/publications.pdf>

Version: 2024-02-01

235
papers

38,999
citations

10956

71
h-index

2883

190
g-index

238
all docs

238
docs citations

238
times ranked

40645
citing authors

#	ARTICLE	IF	CITATIONS
1	Quality of systematic reviews supporting the 2017 ACC/AHA and 2018 ESC/ESH guidelines for the management of hypertension. <i>BMJ Evidence-Based Medicine</i> , 2022, 27, 79-86.	1.7	3
2	Triple Therapy Prevention of Recurrent Intracerebral Disease Events Trial: Rationale, design and progress. <i>International Journal of Stroke</i> , 2022, 17, 1156-1162.	2.9	3
3	Polypills for the prevention of cardiovascular disease: a framework for wider use. <i>Nature Medicine</i> , 2022, 28, 226-229.	15.2	4
4	Association of Low-Dose Triple Combination Therapy vs Usual Care With Time at Target Blood Pressure. <i>JAMA Cardiology</i> , 2022, 7, 645.	3.0	4
5	Text Messages to Improve Medication Adherence and Secondary Prevention After Acute Coronary Syndrome: The TEXTMEDS Randomized Clinical Trial. <i>Circulation</i> , 2022, 145, 1443-1455.	1.6	27
6	Persistence with urate-lowering therapy in Australia: A longitudinal analysis of allopurinol prescriptions. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 4894-4901.	1.1	7
7	Ultra-low-dose quadruple combination blood pressure-lowering therapy in patients with hypertension: The QUARTET randomized controlled trial protocol. <i>American Heart Journal</i> , 2021, 231, 56-67.	1.2	14
8	Combination blood pressure lowering in the presence or absence of background statin and aspirin therapy: a combined analysis of PROGRESS and ADVANCE Trials. <i>Journal of Hypertension</i> , 2021, 39, 1689-1696.	0.3	1
9	An electronic decision support-based complex intervention to improve management of cardiovascular risk in primary health care: a cluster randomised trial (INTEGRATE). <i>Medical Journal of Australia</i> , 2021, 214, 420-427.	0.8	7
10	Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. <i>Lancet</i> , The, 2021, 397, 1625-1636.	6.3	414
11	The impact of Coronavirus disease 2019 (COVID-19) pandemic on migraine disorder. <i>Journal of Neurology</i> , 2021, 268, 4429-4435.	1.8	8
12	Multi-morbidity and blood pressure trajectories in hypertensive patients: A multiple landmark cohort study. <i>PLoS Medicine</i> , 2021, 18, e1003674.	3.9	7
13	Polygenic risk scores predict diabetes complications and their response to intensive blood pressure and glucose control. <i>Diabetologia</i> , 2021, 64, 2012-2025.	2.9	24
14	Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis. <i>Lancet</i> , The, 2021, 398, 1053-1064.	6.3	133
15	Initial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy in patients with hypertension (QUARTET): a phase 3, randomised, double-blind, active-controlled trial. <i>Lancet</i> , The, 2021, 398, 1043-1052.	6.3	74
16	Halving cardiovascular risk with combined blood pressure and cholesterol lowering – Why are we not there yet?. <i>International Journal of Cardiology</i> , 2021, 341, 96-99.	0.8	3
17	A cluster randomized controlled trial of a MedicinesInsight Educational Quality Improvement Programme to improve the diagnosis and treatment of chronic hepatitis C in general practice (the Tj ETQq1 1 0.784614 rgBI /Overlock		
18	The 2016 Joint European Prevention Guidelines and the uses of polypills: Time to update the evidence. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 437-440.	0.8	2

#	ARTICLE	IF	CITATIONS
19	Intensive glucose-lowering and the risk of vascular events and premature death in patients with decreased kidney function: The ADVANCE trial. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 452-457.	2.2	7
20	Association of Low-Dose Triple Combination Therapy With Therapeutic Inertia and Prescribing Patterns in Patients With Hypertension. <i>JAMA Cardiology</i> , 2020, 5, 1219.	3.0	16
21	A digital health intervention for cardiovascular disease management in primary care (CONNECT) randomized controlled trial. <i>Npj Digital Medicine</i> , 2020, 3, 117.	5.7	43
22	Two-drug fixed-dose combinations of blood pressure-lowering drugs as WHO essential medicines: An overview of efficacy, safety, and cost. <i>Journal of Clinical Hypertension</i> , 2020, 22, 1769-1779.	1.0	23
23	Cardiovascular preventive strategies are not conflicting. <i>Lancet, The</i> , 2020, 396, 1879-1880.	6.3	0
24	Regression to the mean in home blood pressure: Analyses of the BP GUIDE study. <i>Journal of Clinical Hypertension</i> , 2020, 22, 1184-1191.	1.0	7
25	Optimising TRIUMPH with 6.25 mg chlorthalidone – Authors' reply. <i>The Lancet Global Health</i> , 2020, 8, e176.	2.9	0
26	Abstract 13354: Effectiveness of a Complex Intervention Based on Electronic Decision Support to Improve Management of Cardiovascular Disease Risk in Primary Healthcare: A Cluster-randomised Controlled Trial. <i>Circulation</i> , 2020, 142, .	1.6	0
27	Reaching cardiovascular prevention guideline targets with a polypill-based approach: a meta-analysis of randomised clinical trials. <i>Heart</i> , 2019, 105, 42-48.	1.2	45
28	Fixed-combination, low-dose, triple-pill antihypertensive medication versus usual care in patients with mild-to-moderate hypertension in Sri Lanka: a within-trial and modelled economic evaluation of the TRIUMPH trial. <i>The Lancet Global Health</i> , 2019, 7, e1359-e1366.	2.9	24
29	Effects of continuous positive airway pressure on depression and anxiety symptoms in patients with obstructive sleep apnoea: results from the sleep apnoea cardiovascular Endpoint randomised trial and meta-analysis. <i>EClinicalMedicine</i> , 2019, 11, 89-96.	3.2	38
30	Modeling the cost effectiveness and budgetary impact of Polypills for secondary prevention of cardiovascular disease in the United States. <i>American Heart Journal</i> , 2019, 214, 77-87.	1.2	26
31	Effects of Blood Pressure Lowering on Clinical Outcomes According to Baseline Blood Pressure and Cardiovascular Risk in Patients With Type 2 Diabetes Mellitus. <i>Hypertension</i> , 2019, 73, 1291-1299.	1.3	26
32	Cardiovascular events with blood pressure lowering in patients with diabetes and systolic blood pressure below 140 mmHg. <i>Journal of Clinical Hypertension</i> , 2019, 21, 689-689.	1.0	1
33	Effect of text messaging on depression in patients with coronary heart disease: a substudy analysis from the TEXT ME randomised controlled trial. <i>BMJ Open</i> , 2019, 9, e022637.	0.8	27
34	Hyperkalemia and renin-angiotensin aldosterone system inhibitor therapy in chronic kidney disease: A general practice-based, observational study. <i>PLoS ONE</i> , 2019, 14, e0213192.	1.1	32
35	Regression to the mean of repeated ambulatory blood pressure monitoring in five studies. <i>Journal of Hypertension</i> , 2019, 37, 24-29.	0.3	32
36	A reply to comments by Lee and colleagues on: Repeated intranasal ketamine for treatment resistant depression – the way to go? Results from a pilot randomised controlled trial. <i>Journal of Psychopharmacology</i> , 2019, 33, 260-261.	2.0	0

#	ARTICLE	IF	CITATIONS
37	Effect of dose administration aids on adherence to self-administered medications: a systematic review protocol. <i>BMJ Open</i> , 2019, 9, e030536.	0.8	1
38	Mobile phone text-messaging interventions aimed to prevent cardiovascular diseases (Text2PreventCVD): systematic review and individual patient data meta-analysis. <i>Open Heart</i> , 2019, 6, e001017.	0.9	56
39	Mobile phone text messaging and app-based interventions for smoking cessation. <i>The Cochrane Library</i> , 2019, 10, CD006611.	1.5	226
40	Does splitting a tablet obtain the accurate dose?. <i>Medicine (United States)</i> , 2019, 98, e17189.	0.4	3
41	Does Co-administration of Antihypertensive Drugs and Statins Alter Their Efficacy and Safety? A Systematic Review and Meta-analysis of Randomized Controlled Trials. <i>Journal of Cardiovascular Pharmacology</i> , 2019, 73, 352-358.	0.8	5
42	Effects of blood pressure-lowering drugs in heart failure. <i>Journal of Hypertension</i> , 2019, 37, 1757-1767.	0.3	7
43	Efficacy and safety of triple versus dual combination blood pressure-lowering drug therapy. <i>Journal of Hypertension</i> , 2019, 37, 1567-1573.	0.3	48
44	Efficacy and safety of dual combination therapy of blood pressure-lowering drugs as initial treatment for hypertension. <i>Journal of Hypertension</i> , 2019, 37, 1768-1774.	0.3	60
45	Effects of blood pressure lowering on cardiovascular events, in the context of regression to the mean. <i>Journal of Hypertension</i> , 2019, 37, 16-23.	0.3	37
46	Acute Increases in Serum Creatinine After Starting Angiotensin-Converting Enzyme Inhibitor-Based Therapy and Effects of its Continuation on Major Clinical Outcomes in Type 2 Diabetes Mellitus. <i>Hypertension</i> , 2019, 73, 84-91.	1.3	40
47	Prevalence trends tell us what did not precipitate the US obesity epidemic. <i>Lancet Public Health</i> , The, 2018, 3, e162-e163.	4.7	69
48	Questionable Conclusions Regarding Blood Pressure End Points. <i>JAMA Internal Medicine</i> , 2018, 178, 575.	2.6	2
49	False reassurance about the consequences of withdrawing antihypertensive drug therapy. <i>Journal of Hypertension</i> , 2018, 36, 447-448.	0.3	0
50	Associations between body mass index and the risk of renal events in patients with type 2 diabetes. <i>Nutrition and Diabetes</i> , 2018, 8, 7.	1.5	32
51	Repeated intranasal ketamine for treatment-resistant depression – the way to go? Results from a pilot randomised controlled trial. <i>Journal of Psychopharmacology</i> , 2018, 32, 397-407.	2.0	66
52	Cost-effectiveness of a fixed dose combination (polypill) in secondary prevention of cardiovascular diseases in India: Within-trial cost-effectiveness analysis of the UMPIRE trial. <i>International Journal of Cardiology</i> , 2018, 262, 71-78.	0.8	18
53	Hypertension. <i>Nature Reviews Disease Primers</i> , 2018, 4, 18014.	18.1	636
54	A protocol for an economic evaluation of a polypill in patients with established or at high risk of cardiovascular disease in a UK NHS setting: RUPEE (NHS) study. <i>BMJ Open</i> , 2018, 8, e013063.	0.8	1

#	ARTICLE	IF	CITATIONS
55	Changes in Albuminuria and the Risk of Major Clinical Outcomes in Diabetes: Results From ADVANCE-ON. <i>Diabetes Care</i> , 2018, 41, 163-170.	4.3	46
56	Cardiovascular disease risk and comparison of different strategies for blood pressure management in rural India. <i>BMC Public Health</i> , 2018, 18, 1264.	1.2	14
57	Fixed-dose combinations for hypertension. <i>Lancet, The</i> , 2018, 392, 819-820.	6.3	22
58	Fixed Low-Dose Triple Combination Antihypertensive Medication vs Usual Care for Blood Pressure Control in Patients With Mild to Moderate Hypertension in Sri Lanka. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 566.	3.8	122
59	Response to â€”SPRINT in context. <i>Journal of Hypertension</i> , 2018, 36, 1602-1603.	0.3	1
60	Blood pressure-lowering treatment strategies based on cardiovascular risk versus blood pressure: A meta-analysis of individual participant data. <i>PLoS Medicine</i> , 2018, 15, e1002538.	3.9	67
61	Comments on Cooper et al.'s review on strategies to mitigate dissociative and psychotomimetic effects from ketamine when used as a fast-acting antidepressant. <i>World Journal of Biological Psychiatry</i> , 2017, 18, 489-489.	1.3	2
62	Cost-effectiveness of a text message programme for the prevention of recurrent cardiovascular events. <i>Heart</i> , 2017, 103, 893.1-894.	1.2	53
63	Quarter-dose quadruple combination therapy for initial treatment of hypertension: placebo-controlled, crossover, randomised trial and systematic review. <i>Lancet, The</i> , 2017, 389, 1035-1042.	6.3	102
64	Side effects and tolerability of combination blood pressure lowering according to blood pressure levels. <i>Journal of Hypertension</i> , 2017, 35, 1318-1325.	0.3	4
65	MEMO: an mHealth intervention to prevent the onset of depression in adolescents: a double-blind, randomised, placebo-controlled trial. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2017, 58, 1014-1022.	3.1	54
66	Cumulative in-trial and post-trial effects of blood pressure and lipid lowering. <i>Journal of Hypertension</i> , 2017, 35, 905-913.	0.3	14
67	Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 951-961.	0.8	23
68	Impact of switching to polypill based therapy by baseline potency of medication: Post-hoc analysis of the SPACE Collaboration dataset. <i>International Journal of Cardiology</i> , 2017, 249, 443-447.	0.8	4
69	Association of Positive Airway Pressure With Cardiovascular Events and Death in Adults With Sleep Apnea. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 156.	3.8	287
70	A personalised or procrustean approach to treating hypertension? â€” Authors' reply. <i>Lancet, The</i> , 2017, 390, 27-28.	6.3	1
71	Redefining blood pressure targets. <i>European Heart Journal</i> , 2017, 38, 1008-1011.	1.0	2
72	Guideline for the diagnosis and management of hypertension in adults â€” 2016. <i>Medical Journal of Australia</i> , 2017, 206, 141-141.	0.8	5

#	ARTICLE	IF	CITATIONS
73	Lost in translation: the gap between what we know and what we do about cardiovascular disease. Medical Journal of Australia, 2017, 206, 51-51.	0.8	0
74	Efficacy and Safety of Quarter-Dose Blood Pressure“Lowering Agents. Hypertension, 2017, 70, 85-93.	1.3	48
75	National drug policy reform for noncommunicable diseases in low-resource countries: an example from Bangladesh. Bulletin of the World Health Organization, 2017, 95, 382-384.	1.5	13
76	Lost in translation: the gap between what we know and what we do about cardiovascular disease. Medical Journal of Australia, 2016, 204, 291-292.	0.8	7
77	Evaluating factors influencing the delivery and outcomes of an incentive-based behaviour change strategy targeting child obesity: protocol for a qualitative process and impact evaluation. BMJ Open, 2016, 6, e012536.	0.8	4
78	Text2PreventCVD: protocol for a systematic review and individual participant data meta-analysis of text message-based interventions for the prevention of cardiovascular diseases. BMJ Open, 2016, 6, e012723.	0.8	16
79	Comparative Cost-Effectiveness of Conservative or Intensive Blood Pressure Treatment Guidelines in Adults Aged 35“74 Years. Hypertension, 2016, 68, 88-96.	1.3	34
80	Accumulating Evidence of Benefits From Intensive Blood Pressure Lowering. Hypertension, 2016, 68, 546-548.	1.3	2
81	Microvascular and Macrovascular Disease and Risk for Major Peripheral Arterial Disease in Patients With Type 2 Diabetes. Diabetes Care, 2016, 39, 1796-1803.	4.3	79
82	More Versus Less Blood Pressure Lowering: An Update. Clinical Therapeutics, 2016, 38, 2135-2141.	1.1	11
83	Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet, The, 2016, 388, 2532-2561.	6.3	1,399
84	Intensive blood pressure lowering “ Authors' reply. Lancet, The, 2016, 387, 2291.	6.3	7
85	Plasma Lipidomic Profiles Improve on Traditional Risk Factors for the Prediction of Cardiovascular Events in Type 2 Diabetes Mellitus. Circulation, 2016, 134, 1637-1650.	1.6	205
86	Mobile phone-based interventions for smoking cessation. The Cochrane Library, 2016, 4, CD006611.	1.5	596
87	Polypill treatments for cardiovascular diseases. Expert Opinion on Drug Delivery, 2016, 13, 1-6.	2.4	33
88	Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON. Diabetes Care, 2016, 39, 694-700.	4.3	184
89	Estimated cardiovascular relative risk reduction from fixed-dose combination pill (polypill) treatment in a wide range of patients with a moderate risk of cardiovascular disease. European Journal of Preventive Cardiology, 2016, 23, 1289-1297.	0.8	13
90	Mobile Telephone Text Messaging for Medication Adherence in Chronic Disease. JAMA Internal Medicine, 2016, 176, 340.	2.6	580

#	ARTICLE	IF	CITATIONS
91	Do polypills lead to neglect of lifestyle risk factors? Findings from an individual participant data meta-analysis among 3140 patients at high risk of cardiovascular disease. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 1393-1400.	0.8	14
92	Effectiveness of fixed dose combination medication (â€”polypillsâ€”™) compared with usual care in patients with cardiovascular disease or at high risk: A prospective, individual patient data meta-analysis of 3140 patients in six countries. <i>International Journal of Cardiology</i> , 2016, 205, 147-156.	0.8	103
93	Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. <i>Lancet, The</i> , 2016, 387, 957-967.	6.3	2,464
94	Effects of Low-Dose and Very Low-Dose Ketamine among Patients with Major Depression: a Systematic Review and Meta-Analysis. <i>International Journal of Neuropsychopharmacology</i> , 2016, 19, pyv124.	1.0	175
95	Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. <i>Lancet, The</i> , 2016, 387, 435-443.	6.3	792
96	Design Considerations in Development of a Mobile Health Intervention Program: The TEXT ME and TEXTMEDS Experience. <i>JMIR MHealth and UHealth</i> , 2016, 4, e127.	1.8	20
97	An integrated general practice and pharmacy-based intervention to promote the use of appropriate preventive medications among individuals at high cardiovascular disease risk: protocol for a cluster randomized controlled trial. <i>Implementation Science</i> , 2015, 11, 129.	2.5	7
98	Process evaluation of the impact and acceptability of a polypill for prevention of cardiovascular disease. <i>BMJ Open</i> , 2015, 5, e008018.	0.8	19
99	The Effect of a Cardiovascular Polypill Strategy on Pill Burden. <i>Cardiovascular Therapeutics</i> , 2015, 33, 347-352.	1.1	25
100	Worldwide access to treatment for end-stage kidney disease: a systematic review. <i>Lancet, The</i> , 2015, 385, 1975-1982.	6.3	1,522
101	Effect of Lifestyle-Focused Text Messaging on Risk Factor Modification in Patients With Coronary Heart Disease. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 1255.	3.8	561
102	Polypill: Progress and Challenges to Global Useâ€”Update on the Trials and Policy Implementation. <i>Current Cardiology Reports</i> , 2015, 17, 121.	1.3	10
103	Redefining Blood-Pressure Targets â€” SPRINT Starts the Marathon. <i>New England Journal of Medicine</i> , 2015, 373, 2175-2178.	13.9	134
104	A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. <i>European Journal of Preventive Cardiology</i> , 2015, 22, 920-930.	0.8	136
105	Reducing Premature Cardiovascular Morbidity and Mortality in People With Atherosclerotic Vascular Disease: The World Heart Federation Roadmap for Secondary Prevention of Cardiovascular Disease. <i>Global Heart</i> , 2015, 10, 99.	0.9	82
106	Evaluating the costs and benefits of using combination therapies. <i>Medical Journal of Australia</i> , 2014, 201, 447-448.	0.8	1
107	An economic case for a cardiovascular polypill? A cost analysis of the Kanyini GAP trial. <i>Medical Journal of Australia</i> , 2014, 201, 671-673.	0.8	18
108	The Evening versus Morning Polypill Utilization Study: the TEMPUS rationale and design. <i>European Journal of Preventive Cardiology</i> , 2014, 21, 425-433.	0.8	10

#	ARTICLE	IF	CITATIONS
109	Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. <i>BMJ</i> , The, 2014, 348, g3318-g3318.	3.0	149
110	Combination Pill for Cardiovascular Diseaseâ€™Reply. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 93.	3.8	0
111	Use of a Multidrug Pill In Reducing cardiovascular Events (LIMPIRE): rationale and design of a randomised controlled trial of a cardiovascular preventive polypill-based strategy in India and Europe. <i>European Journal of Preventive Cardiology</i> , 2014, 21, 252-261.	0.8	35
112	Combination pharmacotherapy to prevent cardiovascular disease: present status and challenges. <i>European Heart Journal</i> , 2014, 35, 353-364.	1.0	73
113	TRiple pill vs Usual care Management for Patients with mild-to-moderate Hypertension (TRIUMPH): Study protocol. <i>American Heart Journal</i> , 2014, 167, 127-132.	1.2	14
114	Coronary artery calcium and polypill therapy. <i>Nature Reviews Cardiology</i> , 2014, 11, 7-8.	6.1	4
115	Personalization of therapy and polypills. <i>Nature Reviews Cardiology</i> , 2014, 11, 307-307.	6.1	0
116	Follow-up of Blood-Pressure Lowering and Glucose Control in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2014, 371, 1392-1406.	13.9	520
117	The effect of active video games by ethnicity, sex and fitness: subgroup analysis from a randomised controlled trial. <i>International Journal of Behavioral Nutrition and Physical Activity</i> , 2014, 11, 46.	2.0	23
118	The association between resting heart rate, cardiovascular disease and mortality: evidence from 112,680 men and women in 12 cohorts. <i>European Journal of Preventive Cardiology</i> , 2014, 21, 719-726.	0.8	83
119	Recruiting equal numbers of indigenous and non-indigenous participants to a â€™polypillâ€™™ randomized trial. <i>International Journal for Equity in Health</i> , 2013, 12, 44.	1.5	12
120	Prospective meta-analysis of trials comparing fixed dose combination based care with usual care in individuals at high cardiovascular risk: The SPACE Collaboration. <i>International Journal of Cardiology</i> , 2013, 170, 30-35.	0.8	29
121	The cost-effectiveness of smoking cessation support delivered by mobile phone text messaging: Txt2stop. <i>European Journal of Health Economics</i> , 2013, 14, 789-797.	1.4	140
122	Effects of a Fixed-Dose Combination Strategy on Adherence and Risk Factors in Patients With or at High Risk of CVD. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 918.	3.8	330
123	Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis. <i>Cmaj</i> , 2013, 185, 949-957.	0.9	232
124	Effects of Intensive Blood Pressure Lowering on Cardiovascular and Renal Outcomes: A Systematic Review and Meta-Analysis. <i>PLoS Medicine</i> , 2012, 9, e1001293.	3.9	389
125	Effects of Blood Pressure Lowering on Intracranial and Extracranial Bleeding in Patients on Antithrombotic Therapy. <i>Stroke</i> , 2012, 43, 1675-1677.	1.0	49
126	Global photographic assessment of men aged 18 to 60 years with male pattern hair loss receiving finasteride 1 mg or placebo. <i>Journal of the American Academy of Dermatology</i> , 2012, 67, 379-386.	0.6	39

#	ARTICLE	IF	CITATIONS
127	Mobile phone-based interventions for smoking cessation. , 2012, 11, CD006611.		308
128	The Efficacy and Tolerability of "Polypills": Meta-Analysis of Randomised Controlled Trials. PLoS ONE, 2012, 7, e52145.	1.1	74
129	MEMO: A Mobile Phone Depression Prevention Intervention for Adolescents: Development Process and Postprogram Findings on Acceptability From a Randomized Controlled Trial. Journal of Medical Internet Research, 2012, 14, e13.	2.1	145
130	Effects of active video games on body composition: a randomized controlled trial. American Journal of Clinical Nutrition, 2011, 94, 156-163.	2.2	219
131	Improving adherence using combination therapy (IMPACT): Design and protocol of a randomised controlled trial in primary care. Contemporary Clinical Trials, 2011, 32, 909-915.	0.8	38
132	Smoking cessation support delivered via mobile phone text messaging (txt2stop): a single-blind, randomised trial. Lancet, The, 2011, 378, 49-55.	6.3	674
133	Does improved access and greater choice of nicotine replacement therapy affect smoking cessation success? Findings from a randomized controlled trial. Addiction, 2011, 106, 1176-1185.	1.7	27
134	Reply to J-P Chaput. American Journal of Clinical Nutrition, 2011, 94, 1156.	2.2	0
135	Do effects of price discounts and nutrition education on food purchases vary by ethnicity, income and education? Results from a randomised, controlled trial. Journal of Epidemiology and Community Health, 2011, 65, 902-908.	2.0	59
136	An International Randomised Placebo-Controlled Trial of a Four-Component Combination Pill ("Polypill") in People with Raised Cardiovascular Risk. PLoS ONE, 2011, 6, e19857.	1.1	114
137	A Theory-Based Video Messaging Mobile Phone Intervention for Smoking Cessation: Randomized Controlled Trial. Journal of Medical Internet Research, 2011, 13, e10.	2.1	122
138	Perindopril-based blood pressure lowering reduces major vascular events in Asian and Western participants with cerebrovascular disease: the PROGRESS trial. Journal of Hypertension, 2010, 28, 395-400.	0.3	32
139	Efficacy and safety of routine blood pressure lowering in older patients with diabetes: results from the ADVANCE trial. Journal of Hypertension, 2010, 28, 1141-1149.	0.3	50
140	Electrochemically controlled drug delivery based on intrinsically conducting polymers. Journal of Controlled Release, 2010, 146, 6-15.	4.8	386
141	Rationale and design of the Kanyini guidelines adherence with the polypill (Kanyini-GAP) study: a randomised controlled trial of a polypill-based strategy amongst Indigenous and non Indigenous people at high cardiovascular risk. BMC Public Health, 2010, 10, 458.	1.2	33
142	Development of a Controlled Release System for Risperidone Using Polypyrrole: Mechanistic Studies. Electroanalysis, 2010, 22, 439-444.	1.5	46
143	Evaluation of physical properties and performance over time of an actuating polypyrrole based drug delivery system. Sensors and Actuators B: Chemical, 2010, 151, 97-102.	4.0	41
144	Responsiveness of generic and disease-specific health-related quality of life instruments to venous ulcer healing. Wound Repair and Regeneration, 2010, 18, 26-30.	1.5	35

#	ARTICLE	IF	CITATIONS
145	Pre-cessation nicotine replacement therapy: pragmatic randomized trial. <i>Addiction</i> , 2010, 105, 1474-1483.	1.7	49
146	Cyclists' attitudes toward policies encouraging bicycle travel: findings from the Taupo Bicycle Study in New Zealand. <i>Health Promotion International</i> , 2010, 25, 54-62.	0.9	24
147	Effects of price discounts and tailored nutrition education on supermarket purchases: a randomized controlled trial. <i>American Journal of Clinical Nutrition</i> , 2010, 91, 736-747.	2.2	199
148	Aspirin for primary prevention: yes or no?. <i>Journal of Primary Health Care</i> , 2010, 2, 92.	0.2	6
149	Mobile phone-based interventions for smoking cessation. <i>Sao Paulo Medical Journal</i> , 2010, 128, 106-107.	0.4	10
150	Aspirin for primary prevention: yes or no?. <i>Journal of Primary Health Care</i> , 2010, 2, 92-9.	0.2	3
151	Developing nutrition education resources for a multi-ethnic population in New Zealand. <i>Health Education Research</i> , 2009, 24, 558-574.	1.0	14
152	Polypyrrole Film as a Drug Delivery System for the Controlled Release of Risperidone. <i>AIP Conference Proceedings</i> , 2009, , .	0.3	8
153	Feasibility, design and conduct of a pragmatic randomized controlled trial to reduce overweight and obesity in children: The electronic games to aid motivation to exercise (eGAME) study. <i>BMC Public Health</i> , 2009, 9, 146.	1.2	30
154	Impact of Recent Prior Opioid Use on Rizatriptan Efficacy. A Post Hoc Pooled Analysis. <i>Headache</i> , 2009, 49, 395-403.	1.8	49
155	Rizatriptan 10mg ODT for Early Treatment of Migraine and Impact of Migraine Education on Treatment Response. <i>Headache</i> , 2009, 49, 687-696.	1.8	18
156	Expanding Access to Triptans: Assessment of Clinical Outcome. <i>Headache</i> , 2009, 49, 1402-1413.	1.8	3
157	Reducing Attention Deficits After Stroke Using Attention Process Training. <i>Stroke</i> , 2009, 40, 3293-3298.	1.0	130
158	Mobile phone-based interventions for smoking cessation. , 2009, , CD006611.		168
159	Cardiovascular treatment gaps: closing, but slowly. <i>New Zealand Medical Journal</i> , 2009, 122, 3564.	0.5	9
160	Efficacy of Rizatriptan for Menstrual Migraine in an Early Intervention Model: A Prospective Subgroup Analysis of the Rizatriptan TAME (Treat A Migraine Early) Studies. <i>Headache</i> , 2008, 48, 226-235.	1.8	27
161	Elimination of Migraine-Associated Nausea in Patients Treated with Rizatriptan Orally Disintegrating Tablet (ODT): A Randomized, Double-Blind, Placebo-Controlled Study. <i>Headache</i> , 2008, 48, 368-377.	1.8	9
162	Efficacy and Tolerability of Coadministration of Rizatriptan and Acetaminophen vs Rizatriptan or Acetaminophen Alone for Acute Migraine Treatment. <i>Headache</i> , 2008, 48, 921-930.	1.8	26

#	ARTICLE	IF	CITATIONS
163	Couch potatoes to jumping beans: A pilot study of the effect of active video games on physical activity in children. <i>International Journal of Behavioral Nutrition and Physical Activity</i> , 2008, 5, 8.	2.0	161
164	Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2008, 358, 2560-2572.	13.9	6,447
165	Honey as a topical treatment for wounds. , 2008, , CD005083.		106
166	Rizatriptan Efficacy in ICHDâ€” Pure Menstrual Migraine and Menstrually Related Migraine. <i>Headache</i> , 2008, 48, 1194-1201.	1.8	25
167	Global burden of blood-pressure-related disease, 2001. <i>Lancet, The</i> , 2008, 371, 1513-1518.	6.3	1,910
168	Can we eliminate inequalities in coronary disease? Absolutely. <i>Lancet, The</i> , 2008, 372, 1612-1613.	6.3	6
169	Chitosan for overweight or obesity. <i>The Cochrane Library</i> , 2008, , CD003892.	1.5	67
170	Maintaining confidentiality of interim data to enhance trial integrity and credibility. <i>Clinical Trials</i> , 2008, 5, 157-167.	0.7	51
171	Elevated total cholesterol: its prevalence and population attributable fraction for mortality from coronary heart disease and ischaemic stroke in the Asia-Pacific region. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2008, 15, 397-401.	3.1	21
172	Will screening individuals at high risk of cardiovascular events deliver large benefits? Yes. <i>BMJ: British Medical Journal</i> , 2008, 337, a1371-a1371.	2.4	27
173	A Multimedia Mobile Phoneâ€”Based Youth Smoking Cessation Intervention: Findings From Content Development and Piloting Studies. <i>Journal of Medical Internet Research</i> , 2008, 10, e49.	2.1	124
174	Cardiovascular risk factors at age 30 following pre-term birth. <i>International Journal of Epidemiology</i> , 2007, 36, 907-915.	0.9	171
175	Energy Expended Playing Video Console Games: An Opportunity to Increase Childrenâ€™s Physical Activity?. <i>Pediatric Exercise Science</i> , 2007, 19, 334-343.	0.5	235
176	Strategies to promote healthier food purchases: a pilot supermarket intervention study. <i>Public Health Nutrition</i> , 2007, 10, 608-615.	1.1	27
177	Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: health effects and costs. <i>Lancet, The</i> , 2007, 370, 2054-2062.	6.3	293
178	International Physical Activity Questionnaire (IPAQ) and New Zealand Physical Activity Questionnaire (NZPAQ): A doubly labelled water validation. <i>International Journal of Behavioral Nutrition and Physical Activity</i> , 2007, 4, 62.	2.0	159
179	Comment on Eletriptan in Migraine Patients Reporting Unsatisfactory Response to Rizatriptan. <i>Headache</i> , 2007, 47, 452-452.	1.8	0
180	Psychological functioning and healthâ€”related quality of life in adulthood after preterm birth. <i>Developmental Medicine and Child Neurology</i> , 2007, 49, 597-602.	1.1	59

#	ARTICLE	IF	CITATIONS
181	Pragmatism and perfection in the prevention of cardiovascular disease. <i>Lancet Neurology</i> , The, 2007, 6, 944-945.	4.9	1
182	Blood pressure and the global burden of disease 2000. Part 1: Estimates of blood pressure levels. <i>Journal of Hypertension</i> , 2006, 24, 413-422.	0.3	126
183	Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. <i>Journal of Hypertension</i> , 2006, 24, 1201-1208.	0.3	262
184	Blood pressure and the global burden of disease 2000. Part II: Estimates of attributable burden. <i>Journal of Hypertension</i> , 2006, 24, 423-430.	0.3	242
185	The value of risk assessment and burden of disease analyses. <i>Journal of Hypertension</i> , 2006, 24, 783-784.	0.3	2
186	Vegetable and fruit intake and mortality from chronic disease in New Zealand. <i>Australian and New Zealand Journal of Public Health</i> , 2006, 30, 26-31.	0.8	27
187	Cardiovascular mortality attributable to high blood cholesterol in New Zealand. <i>Australian and New Zealand Journal of Public Health</i> , 2006, 30, 252-257.	0.8	5
188	Effectiveness of Monetary Incentives in Modifying Dietary Behavior: A Review of Randomized, Controlled Trials. <i>Nutrition Reviews</i> , 2006, 64, 518-531.	2.6	170
189	Efficacy of Rizatriptan 10 mg Administered Early in a Migraine Attack. <i>Headache</i> , 2006, 46, 914-924.	1.8	67
190	Peak Bone Mass After Exposure to Antenatal Betamethasone and Prematurity: Follow-up of a Randomized Controlled Trial. <i>Journal of Bone and Mineral Research</i> , 2006, 21, 1175-1186.	3.1	45
191	Ethnic disparities in nutrition-related mortality in New Zealand: 1997-2011. <i>New Zealand Medical Journal</i> , 2006, 119, U2122.	0.5	11
192	Mortality attributable to higher-than-optimal body mass index in New Zealand. <i>Public Health Nutrition</i> , 2005, 8, 402-408.	1.1	13
193	Nutrition and the burden of disease in New Zealand: 1997-2011. <i>Public Health Nutrition</i> , 2005, 8, 395-401.	1.1	31
194	Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy. <i>Cancer</i> , 2005, 104, 1548-1555.	2.0	113
195	Rethinking the "Diseases of Affluence" Paradigm: Global Patterns of Nutritional Risks in Relation to Economic Development. <i>PLoS Medicine</i> , 2005, 2, e133.	3.9	416
196	Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer After Moderately Emetogenic Chemotherapy. <i>Journal of Clinical Oncology</i> , 2005, 23, 2822-2830.	0.8	418
197	Smoking and Elevated Blood Pressure Are the Most Important Risk Factors for Subarachnoid Hemorrhage in the Asia-Pacific Region. <i>Stroke</i> , 2005, 36, 1360-1365.	1.0	124
198	Antenatal exposure to betamethasone: psychological functioning and health related quality of life 31 years after inclusion in randomised controlled trial. <i>BMJ: British Medical Journal</i> , 2005, 331, 665.	2.4	154

#	ARTICLE	IF	CITATIONS
199	Perindopril-Based Blood Pressureâ€“Lowering Reduces Major Vascular Events in Patients With Atrial Fibrillation and Prior Stroke or Transient Ischemic Attack. <i>Stroke</i> , 2005, 36, 2164-2169.	1.0	100
200	Cardiovascular risk factors after antenatal exposure to betamethasone: 30-year follow-up of a randomised controlled trial. <i>Lancet, The</i> , 2005, 365, 1856-1862.	6.3	406
201	Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk. <i>Lancet, The</i> , 2005, 365, 434-41.	6.3	283
202	Smoking cessation using mobile phone text messaging is as effective in Maori as non-Maori. <i>New Zealand Medical Journal</i> , 2005, 118, U1494.	0.5	80
203	Blood Pressure at 6 Years of Age After Prenatal Exposure to Betamethasone: Follow-up Results of a Randomized, Controlled Trial. <i>Pediatrics</i> , 2004, 114, e373-e377.	1.0	42
204	Leg ulceration and perceived health: a population based case-control study. <i>Age and Ageing</i> , 2004, 33, 236-241.	0.7	36
205	The PROGRESS trial three years later: time for more action, less distraction. <i>BMJ: British Medical Journal</i> , 2004, 329, 970-971.	2.4	10
206	Ethnic Disparities in Risk Factors for Stroke. <i>Stroke</i> , 2004, 35, 1568-1569.	1.0	18
207	Distribution of Major Health Risks: Findings from the Global Burden of Disease Study. <i>PLoS Medicine</i> , 2004, 1, e27.	3.9	206
208	Blood Pressure and Stroke. <i>Stroke</i> , 2004, 35, 776-785.	1.0	535
209	Perindopril-based blood pressure lowering in individuals with cerebrovascular disease. <i>Journal of Hypertension</i> , 2004, 22, 653-659.	0.3	42
210	Do fixed-dose combination pills or unit-of-use packaging improve adherence? A systematic review. <i>Bulletin of the World Health Organization</i> , 2004, 82, 935-9.	1.5	101
211	The emerging role of therapeutic hypothermia in acute stroke. <i>Lancet Neurology, The</i> , 2003, 2, 529.	4.9	31
212	Comparative quantification of health risks: Conceptual framework and methodological issues. <i>Population Health Metrics</i> , 2003, 1, 1.	1.3	363
213	Leg ulceration as a long-term complication of deep vein thrombosis. <i>Journal of Vascular Surgery</i> , 2003, 38, 1331-1335.	0.6	14
214	Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk. <i>Lancet, The</i> , 2003, 361, 717-725.	6.3	499
215	Estimates of global and regional potential health gains from reducing multiple major risk factors. <i>Lancet, The</i> , 2003, 362, 271-280.	6.3	486
216	A cure for cardiovascular disease?. <i>BMJ: British Medical Journal</i> , 2003, 326, 1407-1408.	2.4	53

#	ARTICLE	IF	CITATIONS
217	Efficacy and tolerability of finasteride 1 mg in men aged 41 to 60 years with male pattern hair loss. <i>European Journal of Dermatology</i> , 2003, 13, 150-60.	0.3	81
218	Blood Pressure and Coronary Heart Disease: A Review of the Evidence. <i>Seminars in Vascular Medicine</i> , 2002, 02, 355-368.	2.1	56
219	Selected major risk factors and global and regional burden of disease. <i>Lancet, The</i> , 2002, 360, 1347-1360.	6.3	2,943
220	The emerging role of induced hypothermia in the management of acute stroke. <i>Journal of Clinical Neuroscience</i> , 2002, 9, 502-507.	0.8	37
221	Changing patterns of pharmacological thromboprophylaxis use by orthopaedic surgeons in New Zealand. <i>ANZ Journal of Surgery</i> , 2002, 72, 335-338.	0.3	10
222	Does capture-recapture analysis provide more reliable estimates of the incidence and prevalence of leg ulcers in the community?. <i>Australian and New Zealand Journal of Public Health</i> , 2002, 26, 451-455.	0.8	13
223	The occurrence of leg ulcers in Auckland: results of a population-based study. <i>New Zealand Medical Journal</i> , 2002, 115, 159-62.	0.5	22
224	The lowering of blood pressure after stroke. <i>Lancet, The</i> , 2001, 358, 1994-1995.	6.3	23
225	Reduction of postoperative mortality and morbidity with epidural or spinal anaesthesia: results from overview of randomised. <i>BMJ: British Medical Journal</i> , 2000, 321, 1493-1493.	2.4	1,833
226	No effect of low-dose aspirin for the prevention of heterotopic bone formation after total hip replacement: A randomized trial of 2,649 patients. <i>Acta Orthopaedica</i> , 2000, 71, 129-134.	1.4	42
227	A systematic survey of 13 randomized trials of non-steroidal anti-inflammatory drugs for the prevention of heterotopic bone formation after major hip surgery. <i>Acta Orthopaedica</i> , 2000, 71, 122-128.	1.4	99
228	Treatment of hospitalized patients with complicated Gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. <i>Journal of Antimicrobial Chemotherapy</i> , 1999, 44, 263-273.	1.3	176
229	Less salt does not necessarily mean less taste. <i>Lancet, The</i> , 1999, 353, 1332.	6.3	24
230	Blood Pressure Lowering for the Prevention of Cognitive Decline in Patients with Cerebrovascular Disease. <i>Clinical and Experimental Hypertension</i> , 1997, 19, 843-855.	0.5	19
231	Blood Pressure Lowering for the Secondary Prevention of Myocardial Infarction and Stroke. <i>Hypertension</i> , 1997, 29, 537-538.	1.3	30
232	BLOOD PRESSURE LOWERING IN PATIENTS WITH CEREBROVASCULAR DISEASE: RESULTS OF THE PROGRESS (PERINDOPRIL PROTECTION AGAINST RECURRENT STROKE STUDY) PILOT PHASE. <i>Clinical and Experimental Pharmacology and Physiology</i> , 1996, 23, 444-446.	0.9	11
233	Blood pressure and risk of stroke in patients with cerebrovascular disease. <i>BMJ: British Medical Journal</i> , 1996, 313, 147-147.	2.4	230
234	Systematic Underestimation of Treatment Effects as a Result of Diagnostic Test Inaccuracy: Implications for the Interpretation and Design of Thromboprophylaxis Trials. <i>Thrombosis and Haemostasis</i> , 1995, 73, 167-171.	1.8	57

#	ARTICLE	IF	CITATIONS
235	PHARMACOLOGICAL THROMBOPROPHYLAXIS IN HIP AND KNEE SURGERY: A SURVEY OF NEW ZEALAND ORTHOPAEDIC SURGEONS. ANZ Journal of Surgery, 1994, 64, 167-172.	0.3	15